Media coverage about Intercept Pharmaceuticals (NASDAQ:ICPT) has been trending somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Intercept Pharmaceuticals earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.7229138351405 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the media headlines that may have impacted Accern’s rankings:
Shares of Intercept Pharmaceuticals stock opened at $71.60 on Monday. The company has a debt-to-equity ratio of 21.71, a quick ratio of 4.31 and a current ratio of 4.31. Intercept Pharmaceuticals has a 1 year low of $51.05 and a 1 year high of $135.59.
Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($4.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.39) by ($1.04). The company had revenue of $37.69 million for the quarter, compared to the consensus estimate of $39.01 million. Intercept Pharmaceuticals had a negative net margin of 275.18% and a negative return on equity of 267.95%. The company’s revenue for the quarter was up 173.1% compared to the same quarter last year. During the same period last year, the firm posted ($4.84) earnings per share. analysts expect that Intercept Pharmaceuticals will post -12.6 earnings per share for the current fiscal year.
Several equities analysts have commented on the stock. ValuEngine lowered shares of Intercept Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Goldman Sachs lowered shares of Intercept Pharmaceuticals from a “neutral” rating to a “sell” rating in a report on Wednesday, February 7th. BidaskClub raised shares of Intercept Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, January 25th. Zacks Investment Research raised shares of Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, February 19th. Finally, Citigroup set a $74.00 target price on shares of Intercept Pharmaceuticals and gave the company a “hold” rating in a report on Thursday, December 21st. Four research analysts have rated the stock with a sell rating, ten have given a hold rating and ten have given a buy rating to the stock. Intercept Pharmaceuticals currently has an average rating of “Hold” and an average target price of $128.75.
COPYRIGHT VIOLATION WARNING: This article was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/09/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-intercept-pharmaceuticals-icpt-share-price.html.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.